Ali Alhadab
Impact in
-
- Antifungal resistance and susceptibility
-
- Fungal Infections and Studies
- Nail Diseases and Treatments
Papers in
- Oncology 5
- Lung Cancer Research Studies 2
-
- Fungal Infections and Studies 2
- Pneumocystis jirovecii pneumonia detection and treatment 1
- Co-authors
- Richard C. Brundage (4 shared papers)Nathan C. Bahr (1 shared paper)Lillian Tugume (2 shared papers)David R. Boulware (2 shared papers)SRUTI S VELAMAKANNI (1 shared paper)Darlisha A Williams (2 shared papers)Bożena M Morawski (1 shared paper)Kyle D. Smith (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Clinical Pharmacology & Therapeutics (2 papers)Journal of Pharmacokinetics and Pharmacodynamics (1 paper)Clinical and Translational Science (1 paper)CPT Pharmacometrics & Systems Pharmacology (1 paper)
- Partner nations
- United StatesUnited KingdomSouth Korea
In The Last Decade
Ali Alhadab
11 papers receiving 200 citations
Peers
Comparison fields: 5 of 48
- Infectious Diseases 78
- Epidemiology 110
- Applied Microbiology and Biotechnology 5
- Biological Psychiatry 4
- Pharmacology 27
Countries citing papers authored by Ali Alhadab
This map shows the geographic impact of Ali Alhadab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Alhadab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Alhadab more than expected).
Fields of papers citing papers by Ali Alhadab
This network shows the impact of papers produced by Ali Alhadab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Alhadab. The network helps show where Ali Alhadab may publish in the future.
Co-authors
The 25 scholars most cited alongside Ali Alhadab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 124 | |
| 2 | 2018 | 15 | |
| 3 | 2020 | 14 | |
| 4 | 2024 | 13 | |
| 5 | 2023 | 9 | |
| 6 | 2020 | 7 | |
| 7 | 2019 | 5 | |
| 8 | 2021 | 4 | |
| 9 | 2024 | 4 | |
| 10 | 2020 | 4 | |
| 11 | 2023 | 3 |
About Ali Alhadab
Ali Alhadab is a scholar working on Oncology, Epidemiology, Pulmonary and Respiratory Medicine, Pharmacology and Infectious Diseases, having authored 11 papers that have together received 202 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (3 papers), Lung Cancer Treatments and Mutations (3 papers), Lung Cancer Research Studies (2 papers), Fungal Infections and Studies (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers), Radiomics and Machine Learning in Medical Imaging (1 paper), Pharmaceutical Practices and Patient Outcomes (1 paper) and Pneumocystis jirovecii pneumonia detection and treatment (1 paper). The work is most often cited by research in Infectious Diseases (78 citations), Epidemiology (110 citations), Applied Microbiology and Biotechnology (5 citations), Biological Psychiatry (4 citations) and Pharmacology (27 citations). Ali Alhadab has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include Richard C. Brundage, Nathan C. Bahr, Lillian Tugume, David R. Boulware, SRUTI S VELAMAKANNI, Darlisha A Williams, Bożena M Morawski, Kyle D. Smith, Mahsa Abassi and David B. Meya. Their work appears in journals such as Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics, Journal of Pharmacokinetics and Pharmacodynamics, Clinical and Translational Science and CPT Pharmacometrics & Systems Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.